Gilead Sciences (id:7062 GILD)
93.19 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 12/23/2024 2:01:49 PM)
Exchange open, closes in 1 hour 58 minutes
About Gilead Sciences
Market Capitalization 115.37B
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.
| Headquarters (address) |
333 Lakeside Drive Foster City 94404 CA United States |
| Phone | 650 574 3000 |
| Website | https://www.gilead.com |
| Employees | 18K |
| Sector | Healthcare |
| Industry | Drug Manufacturers General |
| Ticker | GILD |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 62.07 - 98.90 |
| Market Capitalization | 115.37B |
| Dividend yield forward | 3.33 % |
| Dividend yield forward United States (ID:6, base:1858) | 4.48 % |
| P/E trailing | 1.03K |
| P/E forward | 12.46 |
| Price/Sale | 4.08 |
| Price/Book | 6.24 |
| Beta | 3.00 |
| EPS | 5.00 |
| EPS United States (ID:6, base:3382) | 24.33 |
Dividend growth streak
Gilead Sciences has raised their dividend 8.00 years in a row. This is above the 4.499729 year average in the 'Drug Manufacturers General' industry
Forward Annual Dividend Yield
Forward Annual Dividend Yield: Gilead Sciences has raised their dividend 3.33 years in a row. This is below the 42121.954600 year average in the 'Drug Manufacturers General' industry
Compound Average Growth Rate 3 Years
Compound Average Growth Rate 3 Years: Gilead Sciences has raised their dividend 3.32 years in a row. This is below the 23.957000 year average in the 'Drug Manufacturers General' industry
Compound Average Growth Rate 5 Years
Compound Average Growth Rate 5 Years: Gilead Sciences has raised their dividend 5.64 years in a row. This is below the 12.560500 year average in the 'Drug Manufacturers General' industry
Payout Ratio
Payout Ratio: Gilead Sciences has raised their dividend 3.40K years in a row. This is above the 148.467900 year average in the 'Drug Manufacturers General' industry
Self funded year
Gilead Sciences years needed to self fund. This is below the 34.112811 year average in the 'Drug Manufacturers General' industry
Dividend growth streak
Gilead Sciences has raised their dividend 8.00 years in a row. This is above the 4.499729 year average in the 'Drug Manufacturers General' industry
Forward Annual Dividend Yield
Forward Annual Dividend Yield: Gilead Sciences has raised their dividend 3.33 years in a row. This is below the 42121.954600 year average in the 'Drug Manufacturers General' industry
Compound Average Growth Rate 3 Years
Compound Average Growth Rate 3 Years: Gilead Sciences has raised their dividend 3.32 years in a row. This is below the 23.957000 year average in the 'Drug Manufacturers General' industry
Compound Average Growth Rate 5 Years
Compound Average Growth Rate 5 Years: Gilead Sciences has raised their dividend 5.64 years in a row. This is below the 12.560500 year average in the 'Drug Manufacturers General' industry
Payout Ratio
Payout Ratio: Gilead Sciences has raised their dividend 3.40K years in a row. This is above the 148.467900 year average in the 'Drug Manufacturers General' industry
Self funded year
Gilead Sciences years needed to self fund. This is below the 34.112811 year average in the 'Drug Manufacturers General' industry